Interaction Guide · Research summary

Can I take Radix Et Rhizoma Valerianae with Temazepam?

Review Radix Et Rhizoma Valerianae with Temazepam: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Identify the valerian species before taking this root product with temazepam. An unspecified valerian-root name does not establish which safety evidence applies.

What this answer covers

Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence applies only if the product matches.

Supplement or preparation
Radix et Rhizoma Valerianae
Medication ingredient
temazepam

Start with botanical identity

Ask the pharmacist to confirm the Latin species, root or rhizome content, extract and any other ingredients. Do not automatically assume the inventory name means Valeriana officinalis.

What applies if the species matches

NCCIH advises against Valeriana officinalis with sedatives because sleep-inducing effects are possible. This is conditional on identifying the product.

The comparison did not test co-use

In older volunteers, the tested valerian product did not impair performance relative to placebo, while temazepam had dose-related effects. The treatments were given separately; the result does not establish combination safety.

Protect your alertness

Temazepam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.

Evidence and practical considerations

Side effects & toxicity

Identity review and conditional alertness caution are appropriate; exact unidentified-root additive sedation is insufficient.

Exact scope
Radix et Rhizoma Valerianae species unresolved; V. officinalis evidence applies only if the product matches. with Exact oral temazepam; no blanket benzodiazepine metabolic or route transfer.
Medication form and route
oral; other cannabis routes only if explicitly discussed
Timing or duration
Exact duration and dose depend on source; single-dose and chronic use are distinguished.

What remains uncertain

  • Comparator trial used a specific valerian product separately from temazepam. No exact unidentified-root co-use study.

Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral temazepam.

CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolized primarily through conjugation with no active metabolites; not an alprazolam CYP3A profile. Complex sleep behaviors can occur and CNS depressants may increase their risk.

How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.

Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Possible but unproven sleep-inducing effect; advises against use with alcohol or sedatives. Mental dullness can occur; long-term safety is uncertain.

How this applies: Preparation-specific context; not a directly measured temazepam interaction.

No temazepam interaction trial. Chronic use can be followed by withdrawal symptoms when stopped abruptly.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Fourteen healthy older volunteers aged 65-89.

Temazepam produced dose-dependent impairment; valerian did not differ from placebo on tested sedation or psychomotor outcomes.

How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.

Separate exposures, not co-use; tested valerian product is not an unidentified species/root preparation.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries.
Research summary published

Article revision: 660d4cc95548372a

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.